MedTrace Logo

Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA

NCT03544099 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2023-04-11

No results posted yet for this study

Summary

This is a single-arm, multi-center, open-label, phase II trial to examine the efficacy of pembrolizumab for prolonging the one-year disease free survival in nasopharyngeal carcinoma patients with solely detectable EBV DNA after curative chemoradiation. Sixty-three patients will be enrolled in the trial.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

Pembrolizumab

Pembrolizumab 200mg Intravenous Solution

Sponsors & Collaborators

  • National Taiwan University Hospital

    collaborator OTHER

  • Koo Foundation Sun Yat-Sen Cancer Center

    collaborator OTHER

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • Taichung Veterans General Hospital

    collaborator OTHER

  • China Medical University Hospital

    collaborator OTHER

  • Changhua Christian Hospital

    collaborator OTHER

  • National Cheng-Kung University Hospital

    collaborator OTHER

  • National Health Research Institutes, Taiwan

    lead OTHER

Principal Investigators

  • Ruey-Long Hong, PhD · National Taiwan University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-07
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03544099 on ClinicalTrials.gov